Azacitidine

Also known as: Azacytidine

Therapeutic indications

Azacitidine is indicated for:

Population group: both men and women, only adults (18 years old or older)

Azacitidine is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder,
acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
AML with >30% marrow blasts according to the WHO classification.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Azacitidine is contraindicated in the following cases:

Malignant neoplasm of liver